The scientific journal Cancers, of the Multidisciplinary Digital Publishing Institute, published on July 17th, 2020, the study “Economic Evaluation of Population-Based BRCA1/BRCA2 Mutation Testing across Multiple Countries and Health Systems”.
The research indicates that populational testing for mutations in the genes for breast and ovarian cancer can prevent an additional 2,319 to 2,666 breast cancer cases and 327 to 449 ovarian cancer cases per million women compared to the current clinical strategy used, which recommends genetic testing only for high-risk women. The incremental cost-effectiveness ratio was also calculated, from the social and payer perspective.
The Department of Preventive Medicine at the Medical School of the Universidade de São Paulo (FMUSP) participated as one of the collaborative research teams, in addition to institutions in Australia, China, the Netherlands, India and the United Kingdom. The study was led by Prof. Ranjit Manchanda, from Queen Mary University in London, with the support of Dr. Rosa Legood, from the School of Hygiene & Tropical Medicine in London.
“Technological advances and the decreasing costs of genetic tests may offer the possibility of implementing tests in the population. The development of specific implementation strategies for public screening policies in Brazil will be essential for the populational genomics to reach its potential in the prevention and early detection of cancer ”, says Prof. Patrícia Coelho de Soárez, from the FMUSP Preventive Medicine Department, who was at the forefront of studies carried out in Brazil.
To access the full survey, click here.